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IL-15Interleukin (IL)-15, is a cytokine that is important for the maintenance of long-lasting, high-avidity T cell
response to invading pathogens and has, therefore, been used in vaccine and therapeutic platforms as an
adjuvant. In addition to pure protein delivery, plasmids encoding the IL-15 gene have been utilized.
However, it is critical to determine the appropriate dose to maximize the adjuvanting effects. We immunized
rhesus macaques with different doses of IL-15 expressing plasmid in an inﬂuenza non-human primate
immunogenicity model. We found that co-immunization of rhesus macaques with a Flu DNA-based vaccine
and low doses of plasmid encoding macaque IL-15 enhanced the production of IFN-γ (0.5 mg) and the
proliferation of CD4+ and CD8+ T cells, as well as TCM levels in proliferating CD8+ T cells (0.25 mg). Whereas,
high doses of IL-15 (4 mg) decrease the production of IFN-γ and the proliferation of CD4+ and CD8+ T cells
and TCM levels in the proliferating CD4
+ and CD8+ T cells. In addition, the data of hemagglutination
inhibition (HI) antibody titer suggest that although not signiﬁcantly different, there appears to be a slight
increase in antibodies at lower doses of IL-15. Importantly, however, the higher doses of IL-15 decrease the
antibody levels signiﬁcantly. This study demonstrates the importance of optimizing DNA-based cytokine
adjuvants.
© 2009 Elsevier Inc. All rights reserved.Introduction
Studies have shown that strong immune responses help contain
HIV replication by speciﬁc CD4+ and CD8+ T cell proliferation
(Halwani et al., 2008). CD4+ T cells help promote memory CD8+ T
cell proliferation which results in increased effector responses,
including secretion of IFN-γ and cytokine molecules, such as IL-15,
which share the γ-receptor chain subunit and have a role in
generating and maintaining memory T cells (Kutzler et al., 2005;
Chong et al., 2007). Because of the need for a vaccine to be able to
produce a long-term memory response and IL-15's role in the
stimulation, proliferation, and survival of memory CD8+T cells (Ku
et al., 2000; Becker et al., 2002; Moore et al., 2002; Oh et al., 2003;
Sprent, 2003); we sought to ﬁnd an optimal dose for IL-15 cytokine to
be used as an adjuvant in vaccine and therapeutic platforms. In rhesus
macaques chronically infected with SIVmac251, pharmacological
doses of IL-15 have been shown to increase the proliferation of
effector CD4+ and CD8+ T cells (Mueller et al., 2005; Picker et al.,
2006). In uninfected macaques immunized with tetanus toxoid or ayer).
l rights reserved.live inﬂuenza vaccine, IL-15 increased long-term memory response
(Villinger et al., 2004). Our previous study has demonstrated that an
optimized IL-15 immune adjuvant delivered with a DNA vaccine can
impact the cellular immune proﬁle in non-human primates and lead
to an enhanced suppression of viral replication against SHIV (Boyer
et al., 2007).We further assessed the long-term immune protection and
mechanism induced by IL-15 in HIV DNA vaccine. In doing so, we were
able todemonstrate thatDNAvaccineplus IL-15could inducehigh levels
of central memory T cells and T cell responses (Yin et al., 2008).
DNA vaccine therapies are a relatively novel method of vaccina-
tion with the goal to induce broad cellular immunity and humoral
responses in a multitude of infectious disease models. Both viral and
non-viral vaccines have been tested in pre-clinical and clinical
models with variable success (Luxembourg and Lindhoff-Last, 2007)
(Prud'homme, 2006). Furthermore, the developments of new
delivery methods, such as electroporation (EP) (Abdulhaqq and
Weiner, 2008; Kutzler and Weiner, 2008), as well as the use of agents
that improve antigen uptake or presentation, and optimization of the
transgene sequences are overcoming historical drawbacks. Many
studies have shown that the use of EP enhances plasmid uptake and
immune responses by a factor of 5 to 1000 in function of the speciﬁc
model (Bodles-Brakhop and Draghia-Akli, 2008). Nevertheless, doses
of plasmids used in many DNA vaccine studies have been determined
Table 1
Immunization schedule.
Immunization Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
Week 0 Flu DNA Flu DNA Flu DNA Flu DNA Flu DNA Flu DNA
pmac IL-15 pmac IL-15 pmac IL-15 pmac IL-15 pmac IL-15
0.25 mg 0.5 mg 1.0 mg 2.0 mg 4.0 mg
Week 4 Flu DNA Flu DNA Flu DNA Flu DNA Flu DNA Flu DNA
pmac IL-15 pmac IL-15 pmac IL-15 pmac IL-15 pmac IL-15
0.25 mg 0.5 mg 1.0 mg 2.0 mg 4.0 mg
Week 8 Flu DNA Flu DNA Flu DNA Flu DNA Flu DNA Flu DNA
pmac IL-15 pmac IL-15 pmac IL-15 pmac IL-15 pmac IL-15
0.25 mg 0.5 mg 1.0 mg 2.0 mg 4.0 mg
50 J. Yin et al. / Virology 393 (2009) 49–55empirically, or based on data generated in small animal experiments,
which do not rigorously translate to large animal models and
humans; this is moreover true for plasmids encoding for molecular
adjuvants, such as IL-15.
Finding the best possible dose for DNA vaccination that will
promote long-lasting memory cell immunity upon challenge with a
pathogen is needed in order to develop an effective vaccine. In this
manuscript, we present data from a dose ﬁnding study for the IL-15
DNA molecular adjuvant delivered in conjunction with an optimized
consensus inﬂuenza DNA vaccine (Laddy et al., 2008) and identify an
optimumdose for the IL-15 DNA adjuvant, while illustrating the use of
a new IL-15 molecule.
Results
DNA plasmid delivery with electroporation induces robust cellular
immune responses
Six groups of macaques were each immunized by electroporation
(Table 1). We evaluated the induction of a cellular immune response
in each animal by IFN-γ ELISA-linked immunospot (ELISpot) assay.
PBMCs isolated 2 weeks after each immunization were assayed for
inﬂuenza speciﬁc IFN-γ production. After the second immunization,Fig. 1. IFN-γ-production after immunization. Samples were taken 2 weeks after each immun
separation technique and assessed for H5HA antigen- (A) M2eNP antigen- (B) and NA antige
producing cells after third stimulation with H5HA, M2eNP, or NA antigen.animals co-immunized with DNA + 0.5 mg IL-15 induced the highest
H5HA-speciﬁc IFN-γ response (the average of 503 SFCs per million
PBMCs), followed by 0.25 mg IL-15, 1 mg IL-15 and Flu DNA alone
group (control) (Fig. 1A). On the contrary, the high dose IL-15 groups,
2 mg IL-15 and 4 mg IL-15, induced the lowest IFN-γ response to
H5HA (the average of 95 SFCs per million PBMCs and 138 SFCs per
million PBMCs, respectively) (Fig. 1A). Although a small change in the
order of the groups occurred after the third immunization, the 0.5 mg
IL-15 group still induced the highest H5HA-speciﬁc IFN-γ response
(390 SFCs per million PBMCs) and the 4 mg IL-15 group induced the
lowest IFN-γ response (38 SFCs per million PBMCs) (Fig. 1A).
Similar results occurred in the M2eNP-speciﬁc IFN-γ response
after every immunization compared to the IFN-γ response to H5HA
(Figs. 1A and B). After the second and third immunizations, 0.5 mg IL-
15 induced the highest IFN-γ-producing cells to M2eNP (499 SFCs per
million PBMCs), while the 4 mg IL-15 group consistently induced the
lowest IFN-γ-producing cells to M2eNP (80 SFCs per million PBMCs)
(Fig. 1B). However, the results obtained for IFN-γ response to NA
antigen showed that 0.25 mg IL-15 produced the most IFN-γ-secreted
cells and the high dosage IL-15 groups, 2 mg and 4 mg, induced few
IFN-γ-secreted cells (Fig. 1C).
In summary, the animals that received Flu DNA plus a low dose of
IL-15, 0.5mg, induced the higher antigen-speciﬁc IFN-γ response afterization. Peripheral blood mononuclear cells (PBMCs) were isolated by a standard percoll
n- (C) speciﬁc responses by ELISpot. (D) Average SFCs, spot-forming cell levels of IFN-γ-
Fig. 2. Proliferative capacity of antigen-speciﬁc T cells. Peripheral bloodmononuclear cells (PBMCs) from immunizedmacaques are stained with CFSE and stimulatedwith growthmediumH5HA,M2eNP, NA peptides, or concanavalin A (ConA)
for 5 days. Following stimulation, cells were stained for phenotypic markers and analyzed by ﬂow cytometry. Panels A) is gating strategy, B) and C) are CD4 and CD8 average proliferative capacity of CD4+ and CD8+ T cells, respectively, among
the six groups.
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52 J. Yin et al. / Virology 393 (2009) 49–55the third immunization (Fig. 1D), which is the average of 953 SFCs per
million PBMCs. The 4 mg IL-15 dose induced the lowest IFN-γ
response after the third immunization (Fig. 1D). In all, these dataFig. 3. Percent of central memory and effector memory CD4+ and CD8+ T cells in peripheral
and effector memory T cells which were deﬁned as CD28+CD95+ and CD28−CD95+, respec
Data were acquired on an LSRI instrument and analyzed with FlowJo software.showed that high doses of IL-15, 4 mg, inhibited the IFN-γ response
and a low dose, 0.5 mg, gave a robust IFN-γ response after
immunization.blood of macaques after third immunization. (A) Gating strategy shows central memory
tively. (B) An average for all primates is presented for CD4+ or CD8+ TCM and TEM cells.
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macaques
We next assessed the proliferative capacity of the vaccine to
induce CD4+ and CD8+ T cell responses using the CFSE proliferation
assay. PBMCs isolated from macaques 2 weeks after the third
immunization were incubated with CFSE, washed, and stimulated
for 5 days with growth media, and antigens: H5HA, M2eNP, NA, or
concanavalin A (ConA). Following stimulation, T-cell proliferationwas
measured by ﬂow cytometry. We found that the proliferative
responses of CD4+ cells (Fig. 2B) were higher in the low dose of IL-
15 (0.25 mg) group than in two high dose (2 mg and 4 mg) of IL-15
groups (P=0.008 and P=0.038, respectively). In the proliferation of
CD8+ cells (Fig. 2C), low doses of IL-15 (0.25 mg) also induced
signiﬁcantly higher responses than the high dose group (4 mg)
(P=0.04). Moreover, low dose of IL-15 (0.25 mg) plus DNA induced
higher CD8+ T cell proliferative response than DNA alone group
(P=0.03). These results demonstrate that the proliferative capacity of
CD8+ T cells is notably increased in macaques co-immunized with the
Flu DNA plus low doses of IL-15. On the other hand, compared to low
doses of IL-15, high dose can decrease CD4+ and CD8+ T cell
proliferative responses in macaques.
Lower doses of IL-15 increase frequency of central memory T cells in
proliferating T cells
We then compared the frequency of proliferating memory T cell
subsets among the six groups of macaques 2 weeks after third
immunization. Proliferating memory T cells were divided into two
subsets by surface marker expression: central memory T cells (TCM)
were deﬁned as CD28+CD95+ and effectormemory T cells (TEM)were
deﬁned as CD28−CD95+ (Fig. 3A). When we evaluated the frequency
of TCMs and TEMs in proliferating CD4+ cells (Fig. 3B, left panels), we
detected a signiﬁcantly lower percentage of TCMs in the 4mg and 2mg
dosage IL-15 groups (average 22.9% and 10%, respectively) compared
to the 0.25mg IL-15 groups (average 65.5%) (Fig. 3B, upper left panel).
Among the six groups, there was no difference in the percentages of
TEMs (Fig. 3B, lower right panel).
We also evaluated the frequency of TCMs and TEMs in prolifera-
ting CD8+ T cells. The percentages of both TCMs and TEMs were
higher in the 0.25 mg IL-15 group than in the Flu DNA alone group
(P=0.018 and P=0.039, respectively) (Fig. 3B, right panels).
However, high dose of IL-15 groups (4 mg and 2 mg) induced
lower TCMs and TEMs than the low dose group (0.25 mg) (Fig. 3B,Fig. 4. Hemagglutination inhibition (HI) Assay. Sera were collected after each
immunization. HI assays were performed in V-bottom 96-well microtiter plates,
using four hemagglutinating units (HAU) of virus. Hemagglutination inhibition of RBCs
due to an Ag/Ab reaction can be seen when RBCs form a condensed pellet on the bottom
of the well. Titer results were then calculated by taking the reciprocal of the last dilution
of antiserum that inhibits hemagglutination completely.right panels), though the difference did not reach statistical
signiﬁcance. Taken together, the data demonstrate that a low dose
of IL-15 (0.25 mg) can induce higher levels of TCMs in both
proliferating CD4+ and CD8+ T cells as well as higher proliferation
of TEMs in CD8+ T cells (Fig. 3B). In addition, co-immunization with
Flu DNA and high dose IL-15 results in fewer TCMs in proliferating
CD4+ T cells compared to co-immunization with Flu DNA and low
dose IL-15 (Fig. 3B, left panel).
High dose IL-15 decreases humoral immune responses in macaques
Hemagglutination inhibition (HI) assays were performed on
clade-matched (clade 1) H5N1 viruses to compare the ability of our
synthetic vaccine in conjunction with increasing doses of the IL-15
expressing plasmid to induce relevant antibody responses in
primates. As shown in Fig. 4, after the initial immunization, there
was no signiﬁcant difference in the antibody titers among the six
groups. However, following the third immunization, HI titers were
above 1:40 in all macaques and low dose of IL-15 (0.25 mg)
induced higher HI titer compared with high dose group (4 mg)
(P=0.0034). Nevertheless considerable differences were seen
between Flu DNA alone group and any of the IL-15 plasma treated
groups: animals that received the ﬂu vaccine combination in
conjunction with the 0.5 mg IL-15 expressing plasmid displayed
titers of 280±132, median 200. The levels of these titers were more
than double compared to the ﬂu vaccine alone group (120±67,
median 60), while the group that received the ﬂu vaccine in
conjunction with the 4 mg IL-15 expressing plasmid was charac-
terized by an inhibition of responses, with HI titers of 50±10
(median 40). These results suggest that although not signiﬁcantly
different, there appears to be a slight increase in antibodies at lower
doses of IL-15.
IL-15 expression levels in plasma of macaques
Plasma levels of IL-15 were measured on days 0, 2, 4 and 7 after
the 3rd immunization and found that the peak levels in plasma
varied between 1 and 15 pg/mL (data not shown). Fig. 5 shows that
there is no increase in the IL-15 serum levels at the lower IL-15
plasmid doses. At the higher plasmid doses there appears to be an
increase in plasma IL-15 concentrations on day 2 after the 3rd
immunization. However, the trend disappears on day 4 and day 7
(Fig. 5). The data suggest that there does not need to be a measurable
increase in the systemic level of IL-15 for there to be an adjuvant
effect.Fig. 5. IL-15 expression level in serum. Rhesus IL-15 percent change levels were
measured on days 0, 2, 4 and 7 after the third EP using the human IL-15
chemiluminescent immunoassay QuantiGlo kit in all animals.
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In this study, we demonstrated that co-immunization of rhesus
macaques with a Flu DNA-based vaccine and a high dose of plasmid
encoding macaque IL-15 inhibits cellular and humoral immune
response. Compared to low doses of IL-15, high doses of IL-15 (4 mg
and 2 mg) decrease the producing-IFN-γ cells, and CD4+ and CD8+ T
cell proliferation, as well as TCM levels in CD4+ T cells. Whereas low
doses of IL-15 (0.25 mg and 0.5 mg) boost the IFN-γ response, T cell
proliferation, and memory cells in CD4+ and CD8+ T cells. With this,
we can conclude that high doses of plasmid IL-15 inhibit immune
responses in an inﬂuenza non-human primate immunogenicity
model.
IL-15, a cytokine that is important for the maintenance of long-
lasting, high-avidity T cell responses to invading pathogens, achieves
this by supporting the proliferation and survival of CD8+ memory T
cells (Zhang et al., 1998; Ku et al., 2000; Marks-Konczalik et al., 2000;
Waldmann et al., 2001; Becker et al., 2002; Moore et al., 2002; Oh et
al., 2003; Schluns et al., 2004). Because of these properties, IL-15 is
often used in vaccine and therapeutic platforms. IL-15 as an adjuvant
enhances the function and longevity of CD8+ T cells in mice (Kutzler
et al., 2005). Treating PBMCs obtained from HIV-infected patients
with IL-15 enhances anti-HIV immune function (Chehimi et al., 1997).
IL-15 enhances survival and function of HIV-speciﬁc CD8+ T cells in
vitro (Mueller et al., 2003). Recently, IL-15 treatment during acute SIV
infectionwas shown to elicit strong SIV-speciﬁc CD8+ T cell responses
in vivo (Mueller et al., 2008). IL-15's speciﬁcity on CD4+ and CD8+ T
cell proliferation, survival, and function increases the ability for
enhanced immunity against HIV and as a result makes it a good
candidate as an adjuvant for DNA vaccination. Therefore, an optimal
dose of IL-15 DNA adjuvant that will favorably affect the immune
response and promote long-lasting immunity needs to be determined.
However, previous studies have only examined IL-15 dose in small
animal models. Our study used non-human primates to demonstrate
how the dose of plasmid which expresses IL-15 affects the immune
levels post-vaccination. And we have found that a high dose of IL-15
plasmid inhibits immune response. Thus, we propose that a low dose
of IL-15, with its capacity to invoke sustainable cellular and humoral
responses, is a superior cytokine adjuvant that can be used in the
development of an effective vaccine against HIV.
Materials and methods
Animals
Chinese rhesusmacaques were housed at Bioqual in Rockville, MD,
USA. These facilities are accredited by the American Association for
the Accreditation of Laboratory Animal Care International andmet the
National Institutes of Health standards as set forth in the Guidelines
for Care and Use of Laboratory Animals. The University of Pennsylva-
nia Institutional Animal Care and Use Committee (IACUC) reviewed
and approved all procedures carried out by Bioqual.
Plasmid design
The DNA vaccine combination used in this study has been
previously described in Laddy et al. (2008). For non-human primate
(NHP) studies, DNA preparations were made at VGX Pharmaceuticals,
Inc. (The Woodlands, TX) as previously described (Hirao et al., 2008)
and formulated at 10 mg/mL in water plus 1% w/w poly-L-glutamate
sodium salt. In brief, the vaccine consists of a mixture of three
consensus optimized plasmids: a plasmid encoding for the avian
inﬂuenza H5 hemagglutinin (H5HA), a plasmid encoding for neur-
aminidase 1 (N1NA), and a plasmid encoding for a fusion inﬂuenza A
matrix 2 and nucleoprotein sequences (M2eNP). Sequences were
downloaded from the Los Alamos National Laboratory InﬂuenzaSequence Database, and chosen from geographically diverse locations.
MegAlign (DNASTAR, Madison, WI) was used to align the sequences
and generate consensus sequences. The constructs were optimized for
expression, including codon and RNA optimization (GeneArt, Regens-
burg, Germany).
The IL-15 plasmid (pmacIL15ECRO) was optimized for high levels
of expression. The native IL-15 leader peptide sequence (LSP) was
replaced with an IgE leader (Kutzler et al., 2005). Moreover, the codon
usage was adapted. It has been determined that the wildtype
macaque IL15 gene uses rare codons with a high frequency and the
GC content is quite low (35%) which facilitates quick mRNA turnover.
Therefore, GC content was increased (56%) to prolong mRNA half-life.
The ﬁnal design of the gene contained 100% congruence with mature
form of macaque IL15 with the IgE leader replacing the wild type LSP
form.
Immunization
Groups of four Chinese rhesus macaques were immunized three
times at weeks 0, 4 and 8, intramuscularly (IM) with 0.5 mg of each of
the ﬂu DNA antigens for a total of 1.5 mg of ﬂu DNA. An increasing
dose of IL-15-encoding plasmid as listed in Table 1 was co-delivered.
All electroporation procedureswere performed using the CELLECTRA®
device (VGX Pharmaceuticals, Inc., The Woodlands, TX). Three 52 ms
pulses were delivered at a constant current of 0.5 A separated by 1-
second intervals.
ELISpot assay for IFN-γ
ELISpot assays, using IFN-γ reagents (MabTech, Sweden) and
nitrocellulose plates (Millipore, Billerica, MA), were performed
according to the manufacturer's instructions. A positive response
was deﬁned as greater than 50 spot-forming cells (SFC) per million
peripheral blood mononuclear cells (PBMCs) and two times above
background. Data presented in graphs are antigen-speciﬁc responses
with background deducted. Each sample was performed in triplicate
with peptide pools. Peptide pools consist of 15-mer peptides
overlapping by 11 amino acids.
T cell proliferation and memory T cell subset assay
PBMCs were incubated with carboxyﬂuorescein succinimidyl ester
(CFSE) (5 μM) for 8 min at 37 °C. Cells were washed and incubated
with antigens (H5HA, M2eNP and NA peptide pools) at a concentra-
tion of 5 µm/mL for 5 days at 37 °C in 96-well plates. Cultures without
peptide were used to determine the background proliferative
responses. After the 5 day incubation PBMCs were stained with the
following mAbs: anti-CD3 APC-Cy7 (BD-Pharmingen, San Diego, CA),
anti-CD4 PerCP-Cy5.5 (BD-Pharmingen, San Diego, CA), anti-CD8 APC
(BD-Pharmingen, San Diego, CA), anti-CD28 ECD (Beckman Coulter,
Fullerton, CA), and anti-CD95 PE-Cy5 (BD-Pharmingen, San Diego,
CA). Central memory and effector memory T cells were deﬁned as
CD28+CD95+ and CD28−CD95+, respectively (Pitcher et al., 2002).
Stained cells were washed in PBS and ﬁxed (Cell-Fix). Stained and
ﬁxed cells were then obtained on an LSRI cytometer device using
CellQuest software (BD Biosciences) and analyzed with FlowJo
software (Tree Star, Ashland, OR).
Hemagglutination inhibition (HI) assay
Sera were treated with receptor-destroying enzyme (RDE) by
diluting a one part serum with three parts enzyme and incubated
overnight in 37 °C water bath. The enzyme was inactivated by 30 min
incubation at 56 °C followed by addition of six parts PBS for a ﬁnal
dilution of 1/10. HI assays were performed in V-bottom 96-well
microtiter plates, using four hemagglutinating units (HAU) of virus
55J. Yin et al. / Virology 393 (2009) 49–55and 1% horse RBC as previously described (Stephenson et al., 2004).
Viruses used for the HI assay are reassortant strains obtained from the
CDC, inﬂuenza branch (Atlanta, GA): clade 1 A/Viet/1203/2004
(H5N1)/PR8-IBCDC-RG.
IL-15 measurement
Rhesus IL-15 was measured on days 0, 2, 4 and 7 after the third EP
using the human IL-15 chemiluminescent immunoassay QuantiGlo kit
(R&D Systems, No.D1500) in all animals, per manufacturer's
instructions.
Statistical analysis
Statistical analysis of the datawas performed usingMicrosoft Excel
package or Prism GraphPad Software. Data analysis was carried out
with treatment comparisons using the Wilcoxon Signed Rank Test or
one-way ANOVA, where statistically signiﬁcant results are deﬁned as
having a P value of less than 0.05.
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